Kedudukan dalam Saham
#41904
Biostax Corp. is a biopharmaceutical enterprise dedicated to the acquisition,... Biostax Corp. is a biopharmaceutical enterprise dedicated to the acquisition, advancement, and commercialization of various pharmaceutical and biotechnology solutions. A pivotal focus lies on Lodonal, their lead investigational drug candidate, designed as a once-daily immune system modulator aimed at managing both human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Beyond this primary drug, their portfolio encompasses several innovative programs. These include a Global Telehealth platform and an early-stage Medtech initiative leveraging blockchain and smart contract technologies to enhance the security and management of prescriptions and electronic health records. Furthermore, Biostax is developing JKB-122, an experimental small molecule that acts as a long-duration toll-like receptor 4 (TLR4) antagonist, intended for the treatment of autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). Another compound they address is Low Dose Naltrexone, a formula believed to offer immune-modulating advantages pertinent to conditions such as cancer, chronic pain, autoimmune disorders, and anti-aging efforts. The company also pursues development efforts for addressing hyperphosphatemia. Biostax maintains a licensing agreement with Cytocom Inc. and underwent a corporate name change from Immune Therapeutics, Inc. to its current designation in October 2023. The company's operational base is located in Winter Park, Florida.
Harga Saham
$0.0001
Disegerakkan terakhir: 2026-08-11
Perubahan (1 tahun)
-50.00%
Perdagangan Biostax Corp. (BTAX)
Nisbah P/B bagi Biostax Corp. (BTAX)
Nisbah P/B pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Biostax Corp., nisbah P/B semasa (TTM) ialah 0. Pada akhir 2026, nisbah P/B syarikat ialah 0.
Sejarah nisbah P/B untuk Biostax Corp. dari 2026 hingga 2026
Nisbah P/B pada akhir setiap tahun
| Tahun |
Nisbah P/B |
Ubah |
|
Tidak cukup data untuk tarikh yang disediakan. |
Nisbah P/B untuk syarikat atau pesaing yang serupa
| Syarikat |
Nisbah P/B |
Perbezaan Nisbah P/B |
Negara |
|
|
6.2613 |
-
|
US
|
|
|
6.3483 |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
- |
-
|
KR
|
|
|
3.634 |
-
|
BE
|
